Nuveen Asset Management LLC Has $15.67 Million Stock Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Nuveen Asset Management LLC raised its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 44.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 491,107 shares of the company’s stock after buying an additional 150,384 shares during the quarter. Nuveen Asset Management LLC owned 0.39% of Apellis Pharmaceuticals worth $15,671,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Xponance Inc. lifted its stake in Apellis Pharmaceuticals by 5.6% in the fourth quarter. Xponance Inc. now owns 14,072 shares of the company’s stock valued at $449,000 after buying an additional 749 shares during the period. EverSource Wealth Advisors LLC lifted its stake in Apellis Pharmaceuticals by 2,707.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock valued at $25,000 after buying an additional 758 shares during the period. Signaturefd LLC lifted its stake in Apellis Pharmaceuticals by 357.2% in the fourth quarter. Signaturefd LLC now owns 1,175 shares of the company’s stock valued at $37,000 after buying an additional 918 shares during the period. US Bancorp DE lifted its stake in Apellis Pharmaceuticals by 70.0% in the fourth quarter. US Bancorp DE now owns 3,223 shares of the company’s stock valued at $103,000 after buying an additional 1,327 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Apellis Pharmaceuticals by 19.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,615 shares of the company’s stock valued at $307,000 after buying an additional 1,578 shares during the period. 96.29% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, General Counsel David O. Watson sold 5,569 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $25.10, for a total value of $139,781.90. Following the sale, the general counsel now directly owns 138,730 shares of the company’s stock, valued at approximately $3,482,123. This represents a 3.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 6.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on APLS shares. Citigroup dropped their price target on Apellis Pharmaceuticals from $49.00 to $41.00 and set a “buy” rating on the stock in a research note on Thursday. Royal Bank of Canada decreased their price objective on Apellis Pharmaceuticals from $21.00 to $18.00 and set a “sector perform” rating for the company in a report on Thursday, May 8th. The Goldman Sachs Group decreased their price objective on Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a report on Monday, March 3rd. Cantor Fitzgerald began coverage on Apellis Pharmaceuticals in a report on Tuesday, April 29th. They set an “overweight” rating and a $44.00 price objective for the company. Finally, Needham & Company LLC decreased their price objective on Apellis Pharmaceuticals from $40.00 to $29.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. Nine investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $39.89.

Apellis Pharmaceuticals Stock Down 1.9%

Shares of NASDAQ APLS opened at $17.44 on Monday. Apellis Pharmaceuticals, Inc. has a one year low of $16.10 and a one year high of $43.76. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. The business’s fifty day moving average price is $19.62 and its 200-day moving average price is $26.32. The stock has a market capitalization of $2.19 billion, a PE ratio of -8.59 and a beta of 0.73.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The firm had revenue of $149.90 million for the quarter, compared to analysts’ expectations of $197.61 million. During the same period in the prior year, the company earned ($0.54) EPS. The firm’s quarterly revenue was down 3.2% on a year-over-year basis. On average, equities research analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).